- Home
- FTHY vs KROS Comparison
FTHY vs KROS Comparison
Compare FTHY & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHY
- KROS
- Stock Information
- Founded
- FTHY 2020
- KROS 2015
- Country
- FTHY United States
- KROS United States
- Employees
- FTHY N/A
- KROS N/A
- Industry
- FTHY Investment Managers
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- FTHY Finance
- KROS Health Care
- Exchange
- FTHY Nasdaq
- KROS Nasdaq
- Market Cap
- FTHY 540.9M
- KROS 565.0M
- IPO Year
- FTHY N/A
- KROS 2020
- Fundamental
- Price
- FTHY $14.65
- KROS $16.04
- Analyst Decision
- FTHY
- KROS Buy
- Analyst Count
- FTHY 0
- KROS 14
- Target Price
- FTHY N/A
- KROS $20.56
- AVG Volume (30 Days)
- FTHY 176.7K
- KROS 383.7K
- Earning Date
- FTHY 01-01-0001
- KROS 11-05-2025
- Dividend Yield
- FTHY 10.93%
- KROS N/A
- EPS Growth
- FTHY N/A
- KROS N/A
- EPS
- FTHY N/A
- KROS 0.47
- Revenue
- FTHY N/A
- KROS $232,844,000.00
- Revenue This Year
- FTHY N/A
- KROS $5,998.31
- Revenue Next Year
- FTHY N/A
- KROS N/A
- P/E Ratio
- FTHY N/A
- KROS $34.39
- Revenue Growth
- FTHY N/A
- KROS 85820.30
- 52 Week Low
- FTHY $12.66
- KROS $9.12
- 52 Week High
- FTHY $14.74
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- FTHY 49.61
- KROS 62.64
- Support Level
- FTHY $14.63
- KROS $15.34
- Resistance Level
- FTHY $14.84
- KROS $16.11
- Average True Range (ATR)
- FTHY 0.15
- KROS 0.44
- MACD
- FTHY 0.00
- KROS -0.01
- Stochastic Oscillator
- FTHY 56.86
- KROS 94.25
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.